Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 13/20 | 0.35 |
| ▸ | PGR | P06401 | 12/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25664730 | 0.87 | CTSV (0.33) | — | |
| SCHEMBL25664781 | 0.86 | NR3C1 (0.34) | NR3C1NR3C2PGRCA1CA2 | |
| SCHEMBL25880760 | 0.84 | MMP13 (0.37) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL25878180 | 0.80 | ALDH1A1 (0.34) | — | |
| SCHEMBL25881073 | 0.80 | ALDH1A1 (0.34) | — | |
| SCHEMBL25880720 | 0.80 | MMP13 (0.38) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL25881065 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL25877986 | 0.79 | SLC1A3 (0.38) | — | |
| SCHEMBL25878425 | 0.79 | CTSV (0.31) | — | |
| SCHEMBL25877760 | 0.79 | HSD11B1 (0.36) | MMP1MMP2MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | SERPINB1, CTSV, CTSE | NR3C1 4510/4885NR3C2 4673/4885PGR 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.